Public Employees Retirement System of Ohio Increases Stock Position in Elanco Animal Health Incorporated $ELAN

Public Employees Retirement System of Ohio grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 113.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 330,645 shares of the company’s stock after buying an additional 175,412 shares during the period. Public Employees Retirement System of Ohio owned 0.07% of Elanco Animal Health worth $8,137,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. NewEdge Advisors LLC boosted its stake in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Elanco Animal Health during the second quarter valued at approximately $38,000. Root Financial Partners LLC increased its stake in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new position in shares of Elanco Animal Health during the fourth quarter valued at approximately $41,000. Finally, Bessemer Group Inc. boosted its position in shares of Elanco Animal Health by 33.2% in the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 0.4%

ELAN stock opened at $24.01 on Tuesday. The stock has a market capitalization of $12.00 billion, a P/E ratio of -58.56, a P/E/G ratio of 1.44 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a 1-year low of $17.11 and a 1-year high of $27.98. The business has a fifty day moving average price of $24.62 and a 200-day moving average price of $23.99.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same period last year, the firm posted $0.26 earnings per share. Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Paul Herendeen purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the purchase, the director directly owned 111,687 shares of the company’s stock, valued at $2,644,748.16. The trade was a 9.83% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Robert M. Vanhimbergen purchased 4,200 shares of Elanco Animal Health stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the purchase, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on ELAN. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 20th. Citigroup increased their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. UBS Group lifted their price target on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, KeyCorp upped their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.